Seelos Therapeutics Announces Completion of Enrollment of its Phase IIIII Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
| SEEL Stock | USD 0.39 0.11 22.00% |
About 61% of Seelos Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Seelos Therapeutics suggests that many traders are alarmed regarding Seelos Therapeutics' prospects. Seelos Therapeutics' investing sentiment shows overall attitude of investors towards Seelos Therapeutics.
Seelos Therapeutics otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Seelos daily returns and investor perception about the current price of Seelos Therapeutics as well as its diversification or hedging effects on your existing portfolios.
Seelos |
- The randomized, double-blind, placebo-controlled study is evaluating SLS-005 in 160 patients over 24 weeks and Seelos anticipates delivering topline data in the second half of 2023. - Seelos will also enroll patients in an Expanded Access Program t
Read at hawaiinewsnow.com
 |
Seelos Therapeutics Fundamental Analysis
We analyze Seelos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seelos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seelos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Seelos Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Seelos Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Seelos Therapeutics otc stock to make a market-neutral strategy. Peer analysis of Seelos Therapeutics could also be used in its relative valuation, which is a method of valuing Seelos Therapeutics by comparing valuation metrics with similar companies.
Peers
Seelos Therapeutics Related Equities
| EWTX | Edgewise Therapeutics | 18.36 | ||||
| GHRS | GH Research | 3.17 | ||||
| ENTX | Entera Bio | 2.30 | ||||
| PULM | Pulmatrix | 2.15 | ||||
| AKTX | Akari Therapeutics | 2.06 | ||||
| MNMD | Mind Medicine | 1.08 | ||||
| SLNO | Soleno Therapeutics | 0.58 | ||||
| ITOS | Iteos Therapeutics | 1.03 | ||||
| TPST | Tempest Therapeutics | 1.25 | ||||
| ATAI | ATAI Life | 1.50 | ||||
| MOLN | Molecular Partners | 1.87 | ||||
| OPT | Opthea | 2.10 | ||||
| CYBN | Cybin | 4.44 | ||||
| CAPR | Capricor Therapeutics | 4.90 |
Other Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.